Clinical trials: Activities, Motor
Celiac Disease
Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease
This study was conducted to assess the safety and efficacy of larazotide acetate versus placebo in inducing remission in subjects with active celiac disease.
- Trial name
- NCT00620451
- Testing
- larazotide acetate
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 105 people
- Sponsor
- 9 Meters Biopharma, Inc.
Agitation, Schizophrenia
Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia
This is a two-stage adaptive Phase Ib trial design, that will identify two doses (lowest dose with clinical benefit and highest safe dose) in a first stage and better evaluate safety, tolerability and variability of effect in the…
- Trial name
- NCT04010305
- Testing
- Sublingual film containing BXCL501 (Dexmedetomidine)
- Where
- 12 sites in United States
- Volunteers
- 135 people
- Sponsor
- BioXcel Therapeutics Inc
Heart Failure
C-Pulse IDE Feasibility Study- A Heart Assist System
The C-Pulse Feasibility Study is evaluating the safety and performance of a new product for the treatment of heart failure. The product is designed to help reduce the symptoms of heart failure and help patients function better…
- Trial name
- NCT00815880
- Testing
- C-Pulse™ (Implantable Counterpulsation Therapy)
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Nuwellis, Inc.
Agitation, Dementia
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
A study to determine the safety and efficacy of BXCL501 dosing for episodes of agitation associated with dementia when they occur (given as needed [PRN]), for a maximum of 168 doses within a 12-week treatment period.
- Trial name
- NCT05665088
- Testing
- BXCL501
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- BioXcel Therapeutics Inc
Syncope, Cryptogenic Stroke
ConfirmRxTM: Posture and Activity
Insertable Cardiac Monitor's (ICM's) such as Confirm Rx™ are leadless devices implanted for long-term heart rhythm monitoring in the diagnosis and management of clinical conditions such as recurrent unexplained syncope…
- Trial name
- NCT03803969
- Testing
- ConfirmRx (Insertable Cardiac Monitor)
- Where
- 8 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Abbott Medical Devices
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors
This study is conducted in the United States of America (USA). The aim of this study is to assess the long-term (5+ years) postoperative functional outcomes of elective orthopaedic surgery (EOS) patients from previously reported…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- NCT01830712
- Testing
- eptacog alfa (activated)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Novo Nordisk A/S
Sleep Quantity, Sleep Efficiency
Sleep, Physical Activity, and Dietary Habits Among High School Student-athletes and Non-athletes During an Academic Semester
Adolescent's poor sleep habits have been linked to adverse outcomes. Recent advances in activity tracking have provided researchers with cost-effective and non-invasive measurements of sleep in a free-living environment.
- Trial name
- NCT04997603
- Testing
- Accelerometer
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- PepsiCo Global R&D
Dyspnea, Lactic Acidosis
Effect of High Velocity/Hyperoxic Breathing Therapy on Blood Lactate Decline
The study will evaluate the impact of high velocity therapy (HVT) on reduction of work of breathing (as implied by breath frequency) and enhanced blood lactate decline during recovery from a Wingate-type Exercise test.
- Conditions
- Dyspnea, Lactic Acidosis, Muscle, Breathlessness
- Trial name
- NCT05984186
- Testing
- High Velocity Therapy
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Vapotherm, Inc.
Dementia
Fasudil fOr redUcing elopemeNt and Spatial Disorientation
Fasudil, a Rho kinase inhibitor, is believed to reduce wandering behaviors of elopement and getting lost by improving spatial memory and navigation through improvements in hippocampal blood flow. Fasudil is non-sedating.
- Trial name
- FOUND (NCT04793659)
- Testing
- Oral Fasudil 90 mg/day, Oral Fasudil 180 mg/day
- Where
- 11 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Woolsey Pharmaceuticals
Agitation in Patients With Dementia of the Alzheimer's Type
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) was to be based on the "2011 Diagnostic Guidelines for Alzheimer's Disease" issued by the National…
- Trial name
- NCT02442765
- Testing
- AVP-786
- Where
- 126 sites in United States, Estonia and 4 more
- Volunteers
- 387 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Parkinson's Disease
Bradykinesia Subscale Administered Alone Versus Regular Administration: Psychometric Properties
The purpose of this study is to examine whether scores on questionnaires that rate how much Parkinson's Disease (PD) has slowed movements of the body differ when the order of the questions are changed.
- Trial name
- Bravura (NCT00932581)
- Testing
- Bradykinesia UPDRS Motor Full Examination, Bradykinesia subscale of UPDRS Motor Examination
- Volunteers
- 110 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Alzheimer Disease
REXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia
The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.
- Trial name
- NCT06875986
- Testing
- Brexpiprazole (Rexulti)
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Overweight and Obesity
Efficacy of Polyglucosamine for Weight Loss
The polyglucosamine, specification L112 is a medical device and in this clinical trial used for weight reduction of overweight and obese participants.
- Trial name
- NCT02410785
- Testing
- Polyglucosamine
- Where
- 2 sites in Germany, Italy
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Certmedica International GmbH
Ankle Sprain
TRAUMED - a Clinical Trial in Acute Ankle Sprain
TRAUMED - a randomized clinical trial evaluating the efficacy and safety of Traumed® gel in patients with acute ankle sprain.
- Trial name
- TRAUMED (NCT06192420)
- Testing
- Traumeel®, Diclofenac sodium gel 1%
- Where
- Germany
- Volunteers
- 809 people
- Sponsor
- Biologische Heilmittel Heel GmbH
Cancer Prevention
Step up to Health, Nigeria! Impact of 2022 World Cancer Day Walk on Health Behaviors Among Nigerians
Cancer awareness is a critical element of cancer prevention and control. Creating public awareness on risk factors, preventative strategies, and the importance of early screening is the foundation upon which a cancer control…
- Trial name
- NCT05239325
- Testing
- World Cancer Day Walk
- Where
- Nigeria
- Volunteers
- 527 people, healthy volunteers welcome
- Sponsor
- AshtaYoga, LLC
Alzheimer's Disease
A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression.
- Trial name
- NCT01766336
- Testing
- Group 1 ELND005, Group 2 ELND005
- Where
- 46 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- OPKO Health, Inc.
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
The CENTAUR trial was a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases
- Trial name
- CENTAUR (NCT03127514)
- Testing
- AMX0035
- Where
- 25 sites in United States
- Volunteers
- 137 people
- Sponsor
- Amylyx Pharmaceuticals Inc.
Peripheral Neuropathy With Type 2 Diabetes, Peripheral Neuropathy Grade 2 or Greater
Wearable Sensory Prosthesis to Improve Coordination, Walking, and Physical Activity
The goal of this clinical trial is to investigate whether sensory stimulations from a neuroprosthesis device (Walkasins®) can increase physical activity and improve gait quality in persons with peripheral neuropathy (PN).
- Conditions
- Peripheral Neuropathy With Type 2 Diabetes, Peripheral Neuropathy Grade 2 or Greater, Balance, Balance Impairment, Gait Disorders, Fatigue
- Trial name
- NCT07554443
- Testing
- External, lower limb sensory prosthesis
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- RxFunction Inc.
Alzheimer's Disease
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
This study evaluates the safety and efficacy of AADvac1 in the treatment of patients with mild Alzheimer's disease. 60% of participants will receive AADvac1 and 40% of participants will receive placebo.
- Trial name
- ADAMANT (NCT02579252)
- Testing
- AADvac1
- Where
- 42 sites in Austria, Czechia and 6 more
- Volunteers
- 208 people
- Sponsor
- Axon Neuroscience SE
Delayed Onset Muscle Soreness (DOMS)
Study to Assess the Safety, Tolerability, and Effects of CHI-202 to Support Recovery From Physical Activity
The study is designed as a proof of concept, single-center, randomized, double-blind, placebo controlled study to assess the safety and efficacy of CHI-202 (cannabinoids and other ingredients) compared to placebo in the treatment…
- Trial name
- NCT05026164
- Testing
- CHI-202, CHI-101
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation